Greenland Mines Ltd. Common Stock (NASDAQ:GRML – Get Free Report) CFO Jeff Leblanc acquired 14,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 25th. The shares were bought at an average cost of $9.72 per share, for a total transaction of $136,080.00. Following the acquisition, the chief financial officer owned 110,406 shares of the company’s stock, valued at $1,073,146.32. This represents a 14.52% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Greenland Mines Ltd. Common Stock Price Performance
Shares of GRML stock traded up $2.65 during midday trading on Tuesday, reaching $11.20. 1,605,544 shares of the company traded hands, compared to its average volume of 102,120. The firm’s 50 day simple moving average is $0.39 and its two-hundred day simple moving average is $0.41. The firm has a market cap of $1.78 billion, a PE ratio of -35.00 and a beta of 7.13. Greenland Mines Ltd. Common Stock has a 1-year low of $7.81 and a 1-year high of $39.45.
Greenland Mines Ltd. Common Stock (NASDAQ:GRML – Get Free Report) last released its quarterly earnings results on Monday, August 17th. The company reported ($1.50) earnings per share for the quarter.
Hedge Funds Weigh In On Greenland Mines Ltd. Common Stock
Wall Street Analyst Weigh In
GRML has been the topic of a number of research reports. Weiss Ratings cut shares of Greenland Mines Ltd. Common Stock from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, August 11th. Wall Street Zen raised Greenland Mines Ltd. Common Stock to a “sell” rating in a research report on Saturday, May 2nd. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has a consensus rating of “Sell”.
View Our Latest Research Report on GRML
About Greenland Mines Ltd. Common Stock
Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases – cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.
Read More
- Five stocks we like better than Greenland Mines Ltd. Common Stock
- IBM Just Opened Its Mainframes to Arm—Is the Market Missing the Shift?
- Berkshire Boosts Its Bet: This AI Hyperscaler Is Now a Top-3 Holding
- NVIDIA Reveals $21 Billion SpaceX Stake: Signal of Confidence or Circular Financing?
- NVIDIA Earnings Could Move These 3 AI Stocks—Here’s What to Watch
Receive News & Ratings for Greenland Mines Ltd. Common Stock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Greenland Mines Ltd. Common Stock and related companies with MarketBeat.com's FREE daily email newsletter.
